4,315 Shares in Core Laboratories N.V. (CLB) Acquired by Garde Capital Inc.

Garde Capital Inc. acquired a new position in Core Laboratories N.V. (NYSE:CLB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 4,315 shares of the oil and gas company’s stock, valued at approximately $437,000.

A number of other hedge funds have also recently bought and sold shares of the company. Bbva Compass Bancshares Inc. raised its stake in Core Laboratories N.V. by 8.0% in the second quarter. Bbva Compass Bancshares Inc. now owns 10,551 shares of the oil and gas company’s stock worth $1,068,000 after buying an additional 780 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Core Laboratories N.V. by 2.7% in the second quarter. Janney Montgomery Scott LLC now owns 11,676 shares of the oil and gas company’s stock worth $1,182,000 after buying an additional 309 shares during the period. Congress Asset Management Co. MA raised its position in shares of Core Laboratories N.V. by 8.8% in the second quarter. Congress Asset Management Co. MA now owns 558,762 shares of the oil and gas company’s stock worth $56,586,000 after buying an additional 45,258 shares during the period. Howland Capital Management LLC raised its position in shares of Core Laboratories N.V. by 0.8% in the second quarter. Howland Capital Management LLC now owns 106,874 shares of the oil and gas company’s stock worth $10,823,000 after buying an additional 883 shares during the period. Finally, Russell Investments Group Ltd. raised its position in shares of Core Laboratories N.V. by 5.3% in the second quarter. Russell Investments Group Ltd. now owns 808,998 shares of the oil and gas company’s stock worth $81,935,000 after buying an additional 41,026 shares during the period.

Core Laboratories N.V. (CLB) opened at 89.55 on Friday. The stock has a market cap of $3.95 billion, a PE ratio of 54.94 and a beta of 1.60. Core Laboratories N.V. has a 12-month low of $87.83 and a 12-month high of $125.83. The firm has a 50-day moving average of $100.15 and a 200-day moving average of $107.78.

Core Laboratories N.V. (NYSE:CLB) last announced its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.01. The business had revenue of $163.90 million during the quarter, compared to analysts’ expectations of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.35 EPS. Equities analysts predict that Core Laboratories N.V. will post $2.09 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Monday, August 14th. Shareholders of record on Monday, July 17th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Thursday, July 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.46%. Core Laboratories N.V.’s payout ratio is currently 134.15%.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/garde-capital-inc-takes-position-in-core-laboratories-n-v-clb-updated-updated.html.

A number of brokerages have recently commented on CLB. Zacks Investment Research raised shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research report on Friday, April 21st. BidaskClub downgraded shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. UBS AG reiterated a “neutral” rating and set a $110.00 price objective (down from $125.00) on shares of Core Laboratories N.V. in a research note on Wednesday, July 26th. Morgan Stanley dropped their price objective on shares of Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, August 7th. Finally, Scotiabank set a $136.00 target price on shares of Core Laboratories N.V. and gave the company a “hold” rating in a research note on Saturday, April 22nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the stock. Core Laboratories N.V. presently has an average rating of “Hold” and an average price target of $117.17.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply